Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Hartung, Hans Peter ^a   Kieseier, Bernd ^a   Goodin, Douglas S ^b   Arnason, Barry G W ^c   Comi, Giancarlo ^d   Cook, Stuart ^e   Filippi, Massimo ^d   Jeffery, Douglas R ^f   Kappos, Ludwig ^g   Bogumil, Timon ^h   Stemper, Brigitte ⁱ   Sandbrink, Rupert ^a,i   Nakada, Yukiko ^j   Nakajima, Haruhiko ^j   Schwenke, Susanne ⁱ   Lehr, Stephan ⁱ   Heubach, Jürgen ⁱ   Pohl, Christoph ^i,k   Reischl, Joachim ⁱ  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Surgery Brain Research Institutes   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^f CMC Myers Park Clinic MS Center   (United States)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h BAYER CORPORATION   (United States)

ⁱ BAYER PHARMA AG   (Germany)

^j LSI MEDIENCE CORPORATION   (Japan)

^k UNIVERSITY HOSPITAL BONN   (Germany)

more..

Author keywords

Clinical trials randomized controlled; IFNB 1b; Interferon beta; Multiple sclerosis; Neutralizing antibodies; Round robin

Indexed keywords

BETA INTERFERON; BETA INTERFERON 1B; GLATIRAMER; INTERFERON BETA SERINE; MYXOVIRUS PROTEIN A; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL STUDY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; ENZYME ANALYSIS; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOASSAY; LABORATORY TEST; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PROTEIN ANALYSIS; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS;

EID: 84862214154     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-129     Document Type: Article

References (25)

1. Giovannoni G, Munschauer FE, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002, 73:465-469. 10.1136/jnnp.73.5.465, 1738139, 12397132.
2. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2007, 68:977-984. 10.1212/01.wnl.0000258545.73854.cf, 17389300.
3. Gilli F, Bertolotto A, Sala A, Hoffmann F, Capobianco M, Malucchi S, Glass T, Kappos L, Lindberg RL, Leppert D. Neutralising antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain 2004, 127:259-268. 10.1093/brain/awh028, 14607790.
4. Hesse D, Sellebjerg F, Sørensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 2009, 73:372-377. 10.1212/WNL.0b013e3181b04c98, 19652141.
5. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999, 52:1277-1279. 10.1212/WNL.52.6.1277, 10214759.
6. Bellomi F, Scagnolari C, Tomassini V, Gasperini C, Paolillo A, Pozzilli C, Antonelli G. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 2003, 215:3-8. 10.1016/S0022-510X(03)00173-4, 14568120.
7. Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD, Paty DW. Longitudinal analyses of the effects of neutralising antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004, 10:126-138. 10.1191/1352458504ms1004oa, 15124756.
8. Sørensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K, . Danish Multiple Sclerosis Study Group Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005, 65:33-39. 10.1212/01.WNL.0000166049.51502.6A, 15888603, Danish Multiple Sclerosis Study Group.
9. Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A, . Investigators of the 16-Year Long-Term Follow-Up Study Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS. Neurology 2010, 74:1877-1885. 10.1212/WNL.0b013e3181e240d0, 20530324, Investigators of the 16-Year Long-Term Follow-Up Study.
10. Killestein J, Polman CH. Determinants of interferon β efficacy in patients with multiple sclerosis. Nat Rev Neurol 2011, 7:221-228. 10.1038/nrneurol.2011.22, 21364522.
11. Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008, 70:1119-1127.
12. Massart C, Gibassier J, Oger J, Le Page E, Edan G. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay. Clin Chim Acta 2007, 377:185-191. 10.1016/j.cca.2006.09.021, 17123498.
13. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung H-P, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T, . BEYOND Study Group 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomized, multicentre study. Lancet Neurol 2009, 8:889-897. 10.1016/S1474-4422(09)70226-1, 19729344, BEYOND Study Group.
14. Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C, . BEYOND Study Group Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler 2012, 18:181-195. 10.1177/1352458511418629, 21952094, BEYOND Study Group.
15. Files JG, Gray JL, Do LT, Foley WP, Gabe JD, Nestaas E, Pungor E. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998, 18:1019-1024. 10.1089/jir.1998.18.1019, 9877444.
16. Pungor E, Files JG, Gabe JD, Do LT, Foley WP, Gray JL, Nelson JW, Nestaas E, Taylor JL, Grossberg SE. A novel bioassay for the determination of neutralizing antibodies to IFN-beta-1b. J Interferon Cytokine Res 1998, 18:1025-1030. 10.1089/jir.1998.18.1025, 9877445.
17. Grossberg SE, Taylor JD, Siebenlist RE, et al. Biological and immunological assays of human interferons. Manual of Clinical Immunology 1986, 295-299. ASM Publishing, Washington, DC, Rocklin R, 3.
18. Farrell R, Kapoor R, Leary S, Rudge P, Thompson A, Miller D, Giovannoni G. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult Scler 2008, 14:212-218.
19. Lam R, Farrell R, Aziz T, Gibbs E, Giovannoni G, Grossberg S, Oger J. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods 2008, 336:113-118. 10.1016/j.jim.2008.03.014, 18511063.
20. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 2005, 37:360-363.
21. Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung H-P, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010, 9:740-750. 10.1016/S1474-4422(10)70103-4, 20610349.
22. Deisenhammer F, Schellekens H, Bertolotto A. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. J Neurol 2004, 251(suppl 2):II31-II39.
23. McKay F, Schibeci S, Heard R, Stewart G, Booth D. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort. J Immunol Methods 2006, 310:20-29. 10.1016/j.jim.2005.11.011, 16448664.
24. Files JG, Hargrove D, Delute L, Cantillon M. Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay. J Interferon Cytokine Res 2007, 27:637-642. 10.1089/jir.2006.0131, 17784815.
25. Hemmer B, Berthele A. Should we measure the bioavailability of interferon β in vivo in patients with multiple sclerosis?. Nat Clin Pract Neurol 2009, 4:126-127.